New York—June 13, 2011
Osteoarthritis (OA) is one of the most pressing health care challenges of our time, affecting 27 million Americans. In an effort to elucidate the latest information in diagnosis, treatment, research and prevention, Hospital for Special Surgery (HSS) will host an international Osteoarthritis Summit on June 17 and June 18.
The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together a multidisciplinary group of thought leaders from the United States, Canada, Europe and Australia. Renowned physicians, scientists and industry leaders will describe current research, the most promising avenues for future investigation, the latest diagnostic tools and treatments, public health strategies and the most recent information on preventing OA.
“Public health data indicate that the prevalence, impact and economic consequences of osteoarthritis are expected to rise dramatically within the next several decades. Clearly, understanding and preventing this disease is an urgent research challenge,” said Steven Goldring, M.D., chief scientific officer at Hospital for Special Surgery and co-director of the conference.
“By bringing together a group of leading international experts, we will develop a consensus document on future directions for OA research, prevention and treatment,” said Timothy Wright, Ph,D., Kirby chair of orthopedic biomechanics at HSS and co-director of the event.
Orthopedic surgeons, heumatologists, scientists and biomechanical engineers— experts in the major research and clinical aspects of the disease—as well as leaders from the pharmaceutical, device and insurance industries will be among 35 speakers discussing a wide range of topics. The two-day-long event will take place at the Richard Menschel Conference Center at HSS on Friday, June 17, starting at 9 a.m., and on Saturday, June 18, starting at 8 a.m.
Among the subjects to be explored:
The conference will feature distinguished speakers from the National Institutes of Health, the Arthritis Foundation, Hospital for Special Surgery, Rush Medical Center, Brigham and Women’s Hospital, Tufts, Wake Forest, Duke University, McGill University in Canada, the University of Sydney, Genzyme Biosurgery, Pfizer, Inc., Zimmer, Inc., and Aetna.
"We believe the Osteoarthritis Summit will provide vital information about the research, care and innovation necessary to improve the lives of millions of people suffering from OA,” Dr. Goldring said. “Hospital for Special Surgery is proud to be a leader in raising awareness of osteoarthritis and promoting critical research and best practices in patient care."
For a complete list of topics and speakers, go to
Osteoarthritis (OA), the most common form of arthritis, is a serious and painful joint disease that limits mobility and impairs quality of life. Most often affecting the hip and knee, half of all adults will develop symptomatic OA of the knee at some point in their lives.
The socioeconomic burden of the disease is staggering. The economic impact is $128 billion: $81 billion for direct health care expenditures and $47 billion in indirect costs related to lost earnings. OA results in 992,000 hospitalizations and 44 million outpatient visits annually. More than 770,000 hip and knee replacements are performed each year in the United States.
 Arthritis Foundation
 Arthritis Foundation
 National Center for Health Statistics
About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the ninth consecutive year) and No. 3 in rheumatology by U.S.News & World Report (2018-2019). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients and performed more than 32,000 surgical procedures. People from all 50 U.S. states and 80 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The culture of innovation is accelerating at HSS as 130 new idea submissions were made to the Global Innovation Institute in 2017 (almost 3x the submissions in 2015). The HSS Education Institute is the world’s leading provider of education on the topic on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.